Published: September 25, 2025 at 12:45 pm
EMV Capital’s subsidiary Moirai Acquisitions has bought key assets from Destiny Pharma, the AIM-listed MedTech which went into liquidation this summer.
The acquisition, which is centred on Destiny’s antimicrobial XF platform, covers trading its name, website, intellectual property, stock and contracts linked to its lead compound XF-73 and related compounds.
XF-73 is designed to prevent post-surgical site infections by killing bacteria through a rapid mechanism that reduces the likelihood of resistance – an advantage over conventional antibiotics.
Moirai will pay £475,000 upfront in cash, plus up to £2 million in deferred payments tied to future milestones.
These include £600,000 on the start of a Phase 3 clinical trial in the US, £900,000 upon FDA approval for XF-73, and up to £500,000 linked to a potential milestone payment under an existing commercial agreement with a Hong Kong-based pharmaceutical investor.